Dimitris is Senior Vice President of Clinical Development at Zentalis Pharmaceuticals and serves as Head of Global Clinical Development. Prior to joining Zentalis, he was CureVac AG’s Chief Development Officer overseeing preclinical and clinical development activities for oncology, rare diseases/molecular therapies and prophylactic vaccines. Previously, he was Global Head of Clinical Development Oncology at Eisai Inc. overseeing the early and late stage development pipeline in the Oncology Business Unit. He has worked on clinical development projects in all trial phases from preclinical-clinical transition through phases 1 to 3 and has overseen numerous regulatory filings for Nexavar®, Xofigo® as well as Halaven® and Lenvima®. Dimitris first joined the pharmaceutical industry with Bayer HealthCare in 2001 at the Institute of Clinical Pharmacology in Wuppertal, Germany. He was responsible for a number of oncology projects in early development stages and served as Medical Expert, Oncology Expert and Global Clinical Pharmacology Project Leader. As Global Clinical Leader Oncology at Bayer, he was responsible for numerous compounds in different stages and for multiple indications before becoming a Vice President and Oncology Group Head, coordinating the clinical development for Nexavar® and Xofigo®. He is board certified in Internal Medicine, Medical Oncology and Hematology and served as a Senior Consultant in Oncology and Head, Laboratory for Diagnostic Hematology and Immunohematology at the Medical Clinic, University of Cologne, Germany. Dimitris received his medical degree from Cologne University Medical School. He completed his doctoral thesis in experimental oncology research and undertook clinical training in Internal Medicine, Immunology, Oncology and Hematology at the Medical Clinic, University of Cologne, while continuing his clinical research in hematological and solid tumour malignancies as well as experimental and clinical cell cytometry.
Interesting Fact: Dimitris is half German, half Greek, speaks three languages (plus understands two dialects: Bavarian and Kölsch), and has lived in both Germany and Greece before moving to the US. Following this transatlantic relocation to New Jersey, he became a NY Jets fan, without initially realizing what exactly he was getting himself into. J-E-T-S!
How do I contact Dimitris Voliotis?
Has Dimitris Voliotis been buying or selling shares of Zentalis Pharmaceuticals?
Dimitris Voliotis has not been actively trading shares of Zentalis Pharmaceuticals within the last three months. Most recently, Dimitris Voliotis sold 601 shares of the business's stock in a transaction on Monday, February 14th. The shares were sold at an average price of $50.23, for a transaction totalling $30,188.23. Learn More on Dimitris Voliotis' trading history.
Who are Zentalis Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Zentalis Pharmaceuticals?
In the last twelve months, insiders at the sold shares 5 times. They sold a total of 18,302 shares worth more than $205,276.56. The most recent insider tranaction occured on October, 4th when insider Vincent Vultaggio sold 1,603 shares worth more than $5,097.54. Insiders at Zentalis Pharmaceuticals own 3.6% of the company.
Learn More about insider trades at Zentalis Pharmaceuticals. Information on this page was last updated on 10/4/2024.
